摘要
目的:评价以紫杉醇(paclitaxel)为主的、联合5-氟脲嘧啶(5-FU)及顺铂(CDDP)的治疗方案(简称PFC方案)对进展期胃癌进行近期疗效与不良反应的观察。方法:病理确诊的进展期胃癌患者48例,采用紫杉醇35～50mg/m2静滴3h,第1、8、15天;5-FU750mg/m2持续静滴,第1～5天;CDDP20mg/m2,静滴,第1～5天。每4周为1周期,至少2周期评价疗效。结果:全组患者均可评价疗效。其中完全缓解(CR)4例(8.3%),部分缓解(PR)24例(50.0%),稳定(SD)15例(31.3%),进展(PD)5例(10.4%);全组总有效率(ORR)为58.3%;其中低剂量组(紫杉醇35mg/m2)有效率40%(8/20),无CR病例。高剂量组(紫杉醇50mg/m2)有效率71.4%(20/28),CR4例,二者差异有显著性(P=0.04);初治组有效率61.5%(16/26),复治组有效率54.5%(12/22),二者差异无显著性。主要的毒副反应为骨髓抑制、恶心/呕吐和脱发。结论:PFC是治疗进展期胃癌活性较高的方案,毒副反应轻,如患者全身情况允许,可选用高剂量组方案。
Objective:To evaluate the efficacy and toxicity of PFC regimen in the treatment of 48 patients with advanced gastric cancer. Methods:Fourty eight patients with a pathologic diagnosis of stageⅢB or stage Ⅳgastric cancer were enrolled in the study. The patients were treated with paclitaxel 35～50 mg/m2 i nfusion for 3 h on day1,8,15; on day 1 to day 5 infused with 5-FU 750 mg/m2 usi ng an ambulatory pump; and cisplatin 20 mg/m2 infusion on day 1 to day 5. Admini strated in 28 day cycle.Every patient must be treated for two cycles then evalua ted. Results:An objective response was obtained in 58.3%(28/48)of patients ( 4 complete responses and 24 partial responses), whereas 15 patients had no chang e and 5 patients were progressive. The response rate was 71.4%(20/28)in the h igh dose group(paclitaxel 50 mg/m2)and 40%(8/20)in the low dose group(pacl itaxel 35 mg/m2); Significant difference existed between the two groups(P=0.04) ;The response rate was 61.5%(16/26)in naive patients and 54.5%(12/22)in pr etreated patients, no significant difference existed between the two groups. The main toxicities were bone marrow suppression, nausea/vomiting and alopecia. Con clusion:PFC regimen had high activity but comparatively mild toxicity in the tr eatment of advanced gastric cancer. High dose regimen is a precedent choice if p ossible.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2004年第1期40-42,共3页
Journal of Nanjing Medical University(Natural Sciences)
关键词
PFC方案
进展期胃癌
临床疗效
PFC regimen
advanced gastric cancer
clinical study
